Are you routinely testing high grade DLBCL patients who do fit the pathologic criteria for double hit or Burkitt lymphoma for an 11q abberation?
When this entity is identified, are you intensifying your induction treatment regimen instead of standard R-CHOP chemo-immunotherapy?